Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

NCT ID: NCT04393441

Last Updated: 2024-06-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 400 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-06-29
• Study Completion Date: 2021-06-15

Brief Summary

The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (011516X) with Systane® Ultra Multidose for 90 days in participants with Dry Eye Disease (DED).

Conditions

Dry Eye Disease (DED)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Systane® Ultra Multidose

All participants administered 1 to 2 drops of REFRESH PLUS® 3 times daily in each eye for approximately 7 days during a run-in period prior to randomization on Day 1. Participants then administered 1 to 2 drops of Systane® Ultra Multidose in each eye 3 times daily for up to 90 days.

Group Type: ACTIVE_COMPARATOR

Systane Ultra Multidose

Intervention Type: DRUG

Topical eye drops

REFRESH PLUS®

Intervention Type: DRUG

Topical eye drops

011516X (New Artificial Tear Formulation)

All participants administered 1 to 2 drops of REFRESH PLUS® 3 times daily in each eye for approximately 7 days during a run-in period prior to randomization on Day 1. Participants then administered 1 to 2 drops of 011516X in each eye 3 times daily for up to 90 days.

Group Type: EXPERIMENTAL

011516X (New Artificial Tear Formulation)

Intervention Type: DRUG

Topical eye drops

REFRESH PLUS®

Intervention Type: DRUG

Topical eye drops

Interventions

011516X (New Artificial Tear Formulation)

Topical eye drops

Intervention Type: DRUG

Systane Ultra Multidose

Topical eye drops

Intervention Type: DRUG

REFRESH PLUS®

Topical eye drops

Intervention Type: DRUG

Other Intervention Names

8197X

Eligibility Criteria

Inclusion Criteria

• At the Screening (Day -7) and Baseline (Day 1) visits, at least 1 eye must qualify based on corneal and conjunctival staining scores
• Have used an artificial tear product for DED within 6 months of the Screening (Day -7) visit
• Have ability/agreement to continue to wear existing current spectacle correction during the study period (if applicable)
• If using any form of topical ophthalmic cyclosporine (i.e., RESTASIS®) or lifitegrast 5% ophthalmic solution (Xiidra®), participants must be using the drops for ≥90 days prior to the Screening (Day -7) visit and plan to continue without change for the duration of the study
• A female participant is eligible to participate if she is not pregnant (i.e., has a negative in-office urine pregnancy test at Screening [Day -7] and does not verbally report pregnancy at the Day 1 [Baseline] visit; is not breastfeeding, and at least 1 of the following conditions applies:

1. A woman not of childbearing potential (WOCBP) OR

2. A WOCBP who agrees to follow the contraceptive guidance for the duration of the study

Exclusion Criteria

• Have uncontrolled severe systemic disease that, in the assessment of the investigator, would put safety of the participant at risk through participation, or which would prevent or confound protocol-specified assessments (eg, hypertension and diabetes, Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, immunodeficiency disease, etc.)
• Participant has worn contact lenses in the last 90 days prior to the Screening (Day -7) visit and/or participant anticipates contact lens wear during the study
• Have any scheduled or planned systemic surgery or procedure during the study, which in the investigator's opinion, may impact the participant's study participation
• Presence of 1 or more of the following ocular conditions:

• Active ocular infection or non-keratoconjunctivitis sicca (KCS) ocular inflammation
• Active ocular allergy
• History of recurrent herpes keratitis or active disease within 6 months prior to the Screening (Day -7) visit
• Corneal disorder or abnormality that affects corneal sensitivity or normal spreading of the tear film (except superficial punctate keratitis)
• Severe blepharitis or obvious inflammation of the lid margin, which in the judgment of the investigator, may interfere with the interpretation of the study results
• Keratoconjunctivitis sicca secondary to the destruction of conjunctival goblet cells, such as occurs with vitamin A deficiency or scarring such as that with cicatricial pemphigoid, alkali burns, Stevens-Johnson syndrome, trachoma, or irradiation
• Substantial non-KCS keratitis with overlying corneal stain or other significant corneal findings not directly related to DED; in addition, participants with DED signs/symptoms (eg, filamentary keratitis) of a severity where topical monotherapy with an artificial tear would be inappropriate
• The start date of any systemic medication (including over-the-counter [OTC], herbal, prescription, or nutritional supplements) which may affect Dry Eye Disease (DED) or vision is <90 days prior to the Screening (Day -7) visit or a change in dosage is anticipated during the study.

Systemic medications, which may affect DED or vision, include but are not limited to the following: flax seed oil, fish oil, omega-3 supplements, cyclosporine, antihistamines, cholinergic agents, anticholinergics, antimuscarinics, beta blocking agents, tricyclic antidepressants, phenothiazines, estrogen, progesterone, and other estrogen derivatives

• Have occlusion of the lacrimal puncta for either eye, with punctal plugs or cauterization < 6 months prior to the Screening (Day -7) visit or anticipated use of such procedures during the study
• Use of lid-heating therapy (i.e., LipiFlow®, iLUX®, etc.), Meibomian gland probing, or therapeutic Meibomian gland expression in either eye < 6 months prior to the Screening visit (Day -7) or anticipated use during the study
• Have history of ocular/ophthalmic surgery or trauma, which could affect corneal sensitivity and/or tear distribution (eg, cataract surgery, laser-assisted in situ keratomileusis [LASIK], photorefractive keratectomy, or any surgery involving a limbal or corneal incision) within 12 months prior to the Screening (Day -7) visit
• Are currently using topical ocular medication (OTC, herbal or prescription) or TrueTear® (intranasal neurostimulator), or have used topical ocular medication (OTC, herbal or prescription) or TrueTear within 1 month of the Screening (Day -7) visit or plan use of such treatments during the study. Exception: participants who are using the following can be considered:

• Marketed artificial tear product for the management of DED, which must be discontinued at the Screening (Day -7) visit
• Monotherapy for glaucoma or ocular hypertension (OHT) using a prostaglandin analog, beta blocker, alpha-2 agonist, or carbonic anhydrase inhibitor; any topical intraocular pressure (IOP)-lowering medications must have a start date of ≥ 90 days prior to the Screening (Day -7) visit and dosage is not expected to change during the study
• Cyclosporine topical ophthalmic preparation (eg, RESTASIS or other ophthalmic form) or lifitegrast 5% ophthalmic solution (Xiidra), with a start date of ≥ 90 days prior to the Screening (Day -7) visit and dosage is not expected to change during the study NOTE: Participants currently being treated with BOTH an IOP-lowering medication and topical ocular cyclosporine or lifitegrast cannot be enrolled.
• Are currently enrolled in an investigational drug or device study or participation in such a study within 30 days of entry into this study at the Screening (Day -7) visit
• Report an average daily artificial tear use of >6 times per day within 6 months of the Screening (Day -7) visit
• Females who are pregnant, nursing, or planning a pregnancy during the study or females who are of childbearing potential and not using a reliable method of contraception
• Have history of allergies or sensitivity to the study interventions or its components (including all REFRESH and Systane product lines) or diagnostics (eg, topical ocular anesthetic, sodium fluorescein, or lissamine green).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Allergan

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Robinson, MD

Role: STUDY_DIRECTOR

Allergan

Locations

Milton M. Hom, OD, FAAO

Azusa, California, United States

Global Research Management

Glendale, California, United States

Eye Research Foundation

Newport Beach, California, United States

North Bay Eye Associates, Inc.

Petaluma, California, United States

Eric M. White OD Inc

San Diego, California, United States

Wolstan & Goldberg Eye Associates

Torrance, California, United States

Nature Coast Clinical Research

Crystal River, Florida, United States

Bowden Eye & Associates

Jacksonville, Florida, United States

South Florida Research Center, Inc.

Miami, Florida, United States

Vista Health Research, LLC

Miami, Florida, United States

Clinical Research Center of Florida

Pompano Beach, Florida, United States

Georgia Eye Partners

Atlanta, Georgia, United States

Clayton Eye Clinical Research, LLC

Morrow, Georgia, United States

Alliance for Multispecialty Research, LLC

Newton, Kansas, United States

Kannarr Eye Care, LLC

Pittsburg, Kansas, United States

Senior Health Services

Louisville, Kentucky, United States

Moyes Eye Center

Kansas City, Missouri, United States

Ophthalmology Associates

Saint Charles, Missouri, United States

Eye Care Associates of Nevada

Sparks, Nevada, United States

Rochester Ophthalmological Group, PC

Rochester, New York, United States

Wake Forest Health Network Ophthalmology - Oak Hollow

High Point, North Carolina, United States

Eye Care Associates of Greater Cincinnati, Inc. dba Apex Eye

Cincinnati, Ohio, United States

West Bay Eye Associates

Warwick, Rhode Island, United States

Total Eye Care, PA

Memphis, Tennessee, United States

Advancing Vision Research

Nashville, Tennessee, United States

DCT-Shah Research, LLC dba Discovery Clinical Trials

Mission, Texas, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2007-301-005

Identifier Type: -

Identifier Source: org_study_id